

Table 2: Study and Sample Characteristics

Caregiver Characteristics				Child Characteristics				
Location	Study Design	Caregiver Type	Sex/Gender	Mean Age (SD)	Race/Ethnicity	Diagnosis	Sex/Gender	Health Status and Mean Age
United States	Randomized clinical trial Mixed methods	Mothers: n=197	Female: n= 197 Male: n=0	36.3 years	Caucasian: n=90 (45.7%) Hispanic: n=78 (39.6%) African American: n= 15 (7.6%) Other: n=14 (7.1%)	Leukemia: 45.7% Non-neural solid tumors: 14.7% Brain tumors: 14.7% Other: 23.9%	NR	Alive, 8.1 years
Australia	Pilot test with pre-post intervention design Quantitative	Parents: n=11	NR	NR	NR	Blood Cancer: n=5 Brain Cancer: n=2 Solid Cancer: n=1 Coarctation of the Aorta: n=1 Tetralogy of Fallot: n=1 Hyperplastic Left Heart Syndrome: n= 1	Female: n=4 Male: n=7	Alive, NR
United States of America	Pre- post-intervention design Mixed Methods	Parents: n=19	Female: n=14 Male: n=5	35.86 (9.66)	Ethnicity Hispanic/Latino: n=8 Non-Hispanic/Latino: n=36 Race Black/African American: n= 12 White:n= 25 Asian:n=2 Multi-racial: n=1 Race not captured in provided categories: n=33	Leukemia: n=10 Lymphoma: n= 2 Brain tumor: n=1 Solid tumor: n=6	Female: n=21 Male: n=23	Alive, 7.57 years (5.36)
United States of America	Non-randomized pilot clinical trial, single-arm pre-post design Mixed methods	Mothers: n=35 Fathers: n=5 Others (sister/grandmother): n=4	Female: n=39 Male n=5	41.37 years (8.24)	Ethnicity: Hispanic/Latino: n=1 Non-Hispanic/Latino: n=18 Race: Black/African American: n=1 White: n=15 Hawaiian/other Pacific Islander: n=1 Multiracial: n=3 Other:n= 1	Leukemia: n=18 Lymphoma: n=4 Brain Tumor: n=5 Solid Tumor: n=17	Female: n=6 Male: n=13	NR, 6.95 years (4.96)
Sweden	Case study with pre-post design	Mothers: n=1	Female: n=1	38 years (7.2)	NR	Acute Lymphoblastic Leukemia: n=1	Female: n=1 Male: n=0	Alive, 4 years

	Mixed Methods							
Sweden	Pre- post-assessment, parallel randomized controlled trial (RCT)	Parents: n=58	Female: n=39 Male: n=19	38 years (7.2)	NR	Leukemia: n=24 Sarcoma: n=8 Lymphoma: n=3 CNS Tumor: n=7 Other Malignant Disease: n=4	Female: n=25 Male:	Alive, Median= 5 years
	Quantitative							
Sweden	Parallel randomized controlled trial including pre- and post-assessments and a controlled follow-up 12 months after randomization	Parents: n=58	Female: n=39 Male: n=19	38 years (7.2)	NR	Leukemia: n=24 Sarcoma: n=8 Lymphoma: n=3 CNS tumor: n=7 Other malignant disease: n=4	Female: n=25 Male: n=21	Alive, Median=5 years
	Quantitative							
South Korea	Randomized experimental design with pre-intervention, post-intervention, and follow-up testing.	Mothers: n=15	Female: n=15 Male: n=0	37.28 years (3.99)	NR	Leukemia: n=11 Central nervous system: n=1 Non-Hodgkin's lymphoma: n=1 Langerhans cell histiocytosis: n=1 Ewing's sarcoma: n=1	Female: n=10 Male: n=5	NR, Intervention: 5.71 years (2.14), Control: 6.75 years (2.12)
	Quantitative							
The Netherlands	Case Study	Parents: n=2	Female: n=1 Male: n=1	NR	NR	Mucopolysacchari dosis type III (MPS III): n=2	NR	Alive, 10 years
	Mixed Methods							
The Netherlands	Randomized clinical trial	Parents: n=14	Female: n=7 Male: n=7	Intervention: 44.1 years Control: 47.9 years	NR	Mucopolysacchari dosis Type III (MPS III or Sanfilippo Syndrome): n=14	NR	Alive, Intervention: 12.4 years (10.8), Control: 15.9 years (7.8)
	Quantitative							
Israel	Pre- and post-intervention design	Parents: n=8	Female: n=7 Male: n=1	36.0 years (6.7)	NR	Rhabdomy-sarcoma: n=1 Acute lymphoblastic lymphoma: n=1 Hodgkin's nodular sclerosis: n=1	Female: n=3 Male: n=5	NR, 7.5 years (4.8)
	Quantitative							

						Osteosarcoma: n=1 Medoloblastoma 1-2: n=1 ALL eurlly: n=1 ALL eurlly B:n=1 Medoloblastoma post/fosa: n=1		
Germany	Pre/Post Study- Single-group intervention study	Parents: n=23	Female: n=21 Male: n=2	37.0 years	NR	Cystic Fibrosis: n=26	Female: n=12 Male: n=14	Alive, 5.87 years
	Quantitative							
The Netherlands	Randomized control trial	Parents: n=81	Female: n=41 Male: n=40	36.6 years (5.4)	NR	Leukemia: n=17 Malignant Lymphomas: n=7 Wilm's tumor: n=5 Brain tumors: n= 4 Soft tissue sarcomas: n=4 Endocrine tumors: n=2 Other:n= 2	Female: n=23 Male: n=18	Alive, 6.7 years (4.7)
	Quantitative							
South Korea	Quasi- experimental design	Mothers: n=6	Female: n=6 Male: n=0	42 years	East Asian: n=6 South Korean: n=6	Acute myeloid leukemia: n=3 Acute lymphoblastic leukemia: n=2 Chronic lymphoblastic leukemia: n=1	Female: n=2 Male: n=4	Alive (of which n=2 relapsed), 11.33 years
	Mixed methods							
The United States of America	Randomized control trial	Parents: n=16	Female: n=14 Male: n=2	51.8 years (5.0)	White: n=14 Hispanic: n=0 Asian: n=1 Black: n=1 More than 1 race: n=0	Leukemia: n=5 Lymphoma: n=4 CNS tumor: n=2 Other solid tumors: n=8	Female: n=10 Male: n=9	Survivors, 21.0 years (3.7)
	Quantitative							
India	Prospective randomized, single-blind, feasibility pilot study	Parents: n=32	NR	NR	NR	Acute Lymphoblastic Leukemia: n=32	NR	Survivor, Range: 8-12 years
	Mixed Methods							
United States of America	Pre-Post Design, Pilot Study	Parents: n=32	Female: n=19 Male: n=13	NR	Caucasian: n=18 families	Cancer: n=19	Female: n=6 Male: n=13	Survivors, 13.3 years (2.2)

	Mixed Methods				Asian American: n=1 family			
United States of America	Randomized Clinical Trial Quantitative	Parents: n=252	Female: n=146 Male: n=106	Median Maternal Age: 42.9 years, Median Paternal Age: 46.22 years	NR	Leukemias: n= 38 Solid tumors: n=33 Lymphoma: n=31 Bone tumors: n=12 Other: n= 36	Female: n=78 Male: n=72	Survivors, Median Age: 14.32 years
South Korea	Pre- and post-intervention design Mixed Methods	Mothers: n=16	Female: n=16 Male: n=0	NR	NR	Acute lymphoblastic leukemia: n=9 Brain tumor: n=2 Lymphoma: n=1 Neuroblastoma: n=1 Rhabdomyosarcoma: n=2 Osteosarcoma: n=1	Female: n=2 Male: n=14	Alive, Median Age: 9 months
Indonesia	Quasi-Experimental Pre/Post Design Quantitative	Mothers: n=60	Female: n=60	Less than or equal to 30yo: n=13, 31-40yo: n=34, 41-50yo: n= 12 Greater than 50yo: n= 1	NR	Leukemia: n=60	NR	Alive, NR
United States of America	Randomized control trial Quantitative	Parents: n=39	Female: n=34 Male: n=5	36.5 years (6.5)	Caucasian: 55.6% African American: 25% Latino: 5.6% Asian: 11%	Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia: 61.5% Lymphoma: 5.1% Neuroblastoma: 7.7% Sarcoma: 7.7% CNS Disease: 7.7% Rhabdomyosarcoma: 10.3%	NR	Alive, 7.7 years (4.9)
Israel	Pre-Post Design Quantitative	Parent: n=12	NR	41.9 years (7.6)	NR	Hematologic Cancer: n= 14	NR	NR
United States of America and Canada	Randomized Control Trial Quantitative	Mothers: n=141 Fathers: n=20 Others: n=10	NR	NR	White: n=121 Black: n=26 Hispanic: n= 8 Asian: n=7 Other/unknown: n=9	Acute Lymphoblastic Leukemia: n=46 Acute Myeloid Leukemia: n=42 Other leukaemia: n=23	Female: n=70 Male: n=101	12.8 years (3.9)

						Hodgkin's/Non-Hodgkin's Lymphoma: n=18 Solid tumor: n=21 Non-malignancy: n= 19		
Sweden	Pre- and post-intervention design Quantitative	Parents: n=15	Female: n=8 Male: n=7	Range: 35-52 years	NR	Leukemia: n=4 CNS tumor: n=2 Lymphoma: n=1 Sarcoma: n=1 Other malignant disease: n=3	Female: n=7 Male: n=4	Alive, 12.8 years (5.7)
United States of America	Randomized clinical trial Mixed Methods	Parents: n=37	Female: n= 35 Male: n=2	Intervention: 42.8 years (9.21), Control: 39.5 years (7.48)	Caucasian: n=32 African-American: n= 5	Leukemia/Lymphoma: n=29 Solid Tumors: n=8	Female: n=18 Male: n=19	Alive, Intervention: 13.2 years (2.6), Control: 12.9 years (3.4)
United Kingdom	Non-randomized control trial Quantitative	Mothers: n=54	Female: n=54 Male: n=0	NR	NR	Acyanotic: n=27 Cyanotic (corrected): n=9 Cyanotic (complex): n=28	Female: n=29 Male: n=25	NR, 2.9 months (1.6)
Australia	Pre- and post-intervention design Mixed Methods	Mothers: n=10	Female: n=10	39.6 years (7.4)	NR	Genetic developmental and epileptic encephalopathy: n=10	NR	NR, Age Range: 3-5yrs: n=4 6-8yrs: n= 4 9-11yrs: n=1 12-14yrs: n=1
United States of America	Randomized Control Trial Mixed Methods	Parents: n=219	Female: n=213 Male: n=6	Intervention: 30 years (0.5), Control: 30 years (0.6)	NR	Congenital Heart Disease: n=219	Female: n=97 Male: =122	Alive, NR
Iran	Experimental single-case study Mixed Methods	Mothers: n=4	Female: n=4 Male: n=0	39.75 years old	NR	Acute lymphoblastic leukemia: n=3 Neuroblastoma: n=1	Female: n=1 Male: n=3	Alive, 8yrs old
Australia	Randomized Clinical Trial Quantitative	Parents: n=81	Female: n=65 Male: n=16	Intervention: 38.04yrs (6.02). Control: 36.45yrs (6.74)	Total Group: Aboriginal or Torres Strait Islander: n=1	Cardiology: n=22 Oncology: n=28 Pediatric Intensive Care Unit: n=24	NR	Alive, NR
United States of America	Randomized Non-Inferiority Control Trial	Parents: n=621	Female: n=549 Male: n=72	Intervention: 37 yrs old (8.6). Control: 36.7 yrs old (8.8)	White: n=388 Black: n=77 Unknown: n= 138	Acute Lymphoblastic Leukemia (ALL): n=229	Female: n=280 Male: n=345	Alive; Intervention: 8.3yrs (5.5),

	Quantitative					Other Leukemia: n=70 Hodgkin's Lymphoma/Non- Hodgkin's Lymphoma: n=54 Solid Tumor: n=154 Brain Tumor: n=53 Other: n=65		Control: 8.2yrs (5.5)
Australia	Non- randomized, pre-post assessment design with 6- month follow- up Mixed methods	Parents: n=12	NR	40.2 years (6.7)		Cancer Diagnosis: n=5 Cardiac Diagnosis: n=3 Transposition of Great Arteries: n=1 Interrupted Aortic Arch: n=1 Hyperplastic Left Heart Syndrome: n=1	Female: n=4 Male: n=4	Alive, NR
United States of America	Randomized Control Trial Mixed Methods	Parents: n=16	NR	Intervention: 35 yrs (8.5). Control: 32.7 yrs (4.9)	African American: = 0 White: n=7 Other:n= 1 Unknown/Not Reported: n= 8	Leukemia: n=9 Tumor: n=7	Female: n=8 Male: n=8	Alive; Intervention: 5.4yrs (1.9), Control: 5.6yrs (1.7)
United States of America	Two-arm randomized clinical trial Quantitative	Mothers: n=92	Female: n=92 Male: n=0	Intervention: 34.7yrs (6.6), Control: 36yrs (6.67)	Black, not Hispanic: n=9 Hispanic: n= 21 Native American: n=1 White, not Hispanic:n=56 Other: n=5	ALL: n=37 AML:n=8 Lymphoma:n=10 Brain tumor: n=13 Other cancer diagnosis: n=24	NR	NR; Intervention: 97.3mo (62.5), Control: 102.4mo (71.1)
United States of America and Israel	Two Arm Randomized Control Trial Quantitative	Mothers: n=429	Female: n=429 Male: n=0	Intervention: 35yrs, Control: 36yrs	Black, Not Hispanic: n=23 Hispanic: n=112 American Indian:n= 6 Asian:n= 6 White, Not Hispanic:n= 214 Other- Mixed:n= 56	Leukemia: n=182 Brain Tumor: n=64 Other Tumor: n=127 Non-Hodgkin's Lymphoma: n=34 Hodgkin's Disease: n=19	Female: n=210 Male: n=219	Alive, NR
United States of America	Randomized Clinical Trial Quantitative	Mothers: n=309	Female: n=309 Male: n=0	Intervention: 36.3 yrs (8.1), Control: 38.3 yrs (8.3)	Hispanic: n=135 White: n=133 Black: n=22 Other: n= 19	Leukemia: n=142 Solid Tumor: n=45 Brain Tumor: n=36	Female: n=144 Male: n=165	Alive; Intervention: 8.2yrs (5.7), Control: 9.4yrs (6.0)

						Other: n=86		
Denmark	Randomized Control Trial Quantitative	Parents: n=204	Female: n=109 Male: n=95	36.5yrs	NR	Leukemia/Lymphoma: n=55 CNS: n=16 Other: n=38	Female: n=42 Male: n=65	Alive; 1.26yrs
United States of America	Randomized Controlled Trial Quantitative	Biological mothers: n=43 Biological fathers: n=5 Grandmothers: n=3 Adopted mother: n=1 Aunt: n=1	Female: n=49 Male: n=5	Intervention: 35.16yrs (7.35), Control: 38.32yrs (8.65)	White: n=34 African American: n=16 Latino: n=3	Leukemia: n=24 Other cancer: n=18 Sickle cell disease: n=5 Other: n=7	Female: n=24 Male: n=30	Alive, NR
Iran	Randomized Clinical Trial Quantitative	Mothers: n=100	Female: n=100 Male: n=0	Intervention: 33.32yrs (6.76), Control: 35.34yrs (6.08)	NR	Cancer: n=100	Female: n=44 Male: n=56	NR, Intervention: 5.85yrs (2.75), Control: 5.00yrs (3.02)
United States of America	Randomized Control Trial Mixed Methods	Families: n=76	Female: n=NR Male: NR	Median: 36yrs old	NR	Leukemia/Lymphoma: n=42 Solid tumors: n=19 Brain tumours: n=15	Female: n=35 Male: n=41	Alive, Median: 6yrs
United States of America	Randomized Control Trial Mixed methods	Mothers: n=22	Female: n=22 Male: n=0	Intervention: 37.2yrs (5.2), Control: 36.5yrs (8.5)	NR	Ewing Sarcoma: n=5 Neuroblastoma: n=5 Acute Myeloid Leukemia: n=4 Acute Lymphoblastic Leukemia: n=3 Osteosarcoma: n=1 Hodgkin's Lymphoma: n=1 Non-Cancerous Disorder: n=3 (All n=22 had bone marrow transplant)	Female: n=5 Male: n=17	Alive; Intervention: 9.4yrs (4.5), Control: 8.0yrs (5.2)
Sweden	Two – Armed Randomized Control Trial Mixed Methods	Parents: n=21	Female: n=14 Male: n=7	Intervention: 49.9yrs (5.8), Control: 45.6yrs (5.5)		Cancer: n=21	Female: n=9 Male: n=12	Passed; NR

United States of America	Pre/Post Pilot Study Quantitative	Parents: n=5	Female: n=4 Male: n=1	NR	Caucasian: n=2 Latino: n=1 African American: n=1 Caribbean; n=1	Acute Lymphoblastic Leukemia: n=4 Neuroblastoma: n=1	Female: n=3 Male: n=2	Alive; 6.3yrs
Australia	Randomized controlled trial Quantitative	Parents: n=67	Female: n=65 Male: n=2	Intervention #1: 38.67yrs (5.55), Intervention #2: 37.88 (9.39), Control: 39.65yrs (6.09)	NR	Cerebral Palsy: n=67	Female: n=65 Male: n=2	Alive; Intervention #1: 5.31yrs (2.89), Intervention #2: 5.35yrs (3.29), Control: 5.00yrs (3.24)
Australia	Randomized controlled trial Quantitative	Parents: n=67	Female: n=63 Male: n=4	NR	NR	Cerebral Palsy: n=67	Female: n=19 Male: n=48	Alive; Intervention 5yrs 8mo (2.36), Control: 5yrs 6mo (2.6)
China	Randomized controlled trial Quantitative	Parents: n=85	Female: n=44 Male: n=41	Intervention Median: 41.0yrs, Control Median: n=41.0yrs	NR	Osteosarcoma: n=46	Female: n=17 Male: n=29	Alive; Intervention Median: 13.0yrs, Control Median: 12.5yrs
China	Prospective randomized controlled study Quantitative	Parents: n=109	Female: n=NR Male: n=NR	NR	NR	Patent Ductus Arteriosus: n=NR	NR	Alive; NR
United States of America	Pre-post design Mixed methods	Parents: n=12	Female: n=11 Male: n=1	48.4yrs (7.0)	NR	Leukemia: n=6 Lymphoma: n=4 Sarcoma: n=2	Female: n=8 Male: n=8	Alive; 14.8yrs (2.1)